




Obesity prevalence has increased drastically over the last couple of 
decades. Obesity increases an individual’s risk of health complications such as 
cardiovascular disease, hypertension, and other chronic conditions. Obesity has 
been related to an increased susceptibility to infection and complications from the 
influenza virus. In the present study, the immune responses to the influenza 
vaccine between races in obese women will be compared by determining the 
percent increases in immunoglobulin G subtype levels from pre to post 
vaccination.  To accomplish this, serum was collected from study participants 
and tested for antibody levels pre and post vaccination using an indirect enzyme-
linked immunosorbent assay. For IgG1 and IgG3, average percent increases pre 
to post vaccination displayed no difference between African American women 
and Caucasian women. IgG2 was not present in detectable levels in the 
population studied and was not able to be analyzed. For IgG4, the average 
percent increase pre to post vaccination displayed a statistically significant 
difference between African American women and Caucasian women. African 
Americans had a significantly lower average percent increase in IgG4 pre to post 
vaccination compared to Caucasians. This suggests that there may be lower 
levels of IgG4 in African American women in general compared to Caucasian 
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1.1 The Obesity Epidemic: 
Obesity has become an increasing public health concern in the United 
States in recent years. There has been a dramatic increase in obesity in the 
United States from 1990 through 2010, increasing from a prevalence of 12% in 
1990 to a prevalence of 35.7% in 20103. Obesity is a term that describes a range 
of weights that is greater than what is generally considered healthy for a given 
height. This range of weight has been shown to increase the likelihood of certain 
diseases and other health problems, such as diabetes, hypertension and cancer. 
Each year, over 300,000 adults in the U.S. will die from obesity related causes2. 
One method of measuring obesity is using BMI, or body mass index. BMI 
is used in adults to measure body fat based on height and weight using the 
formula; BMI = (weight in kilograms)/(height in meters)2. According to the 
National Institutes of Health, a healthy weight BMI is between 18.5-24.9 kg/m2, 
underweight is below 18.5 kg/m2, overweight is between 25.0-29.9 kg/m2, and 
obese individuals are 30.0 kg/m2 and above5. However, BMI should be used 
cautiously. BMI does not directly measure body fat and may identify some people 
as overweight even if they do not have excess body fat, such as athletes with 
high muscle mass1. 
A variety of factors including behavior, environment, and genetic factors 
can cause an individual to be overweight or obese. Positive energy imbalance, or 
consuming more calories than expending through physical activity, contributes to 
fat gain. Furthermore, obesogenic environments such as food deserts or areas 
without sidewalks or parks can influence poor nutritional intake or lack of physical 
activity.  These factors have been a target in public health prevention. Genes 
may also play a role in obesity and enhance the effects of an obesogenic 
environment4. 
Obesity prevalence varies greatly in the United States depending on race, 
sex, and age. Specifically, the prevalence of obesity is significantly varied 
between racial and ethnic groups. Non-Hispanic Blacks have the highest age-
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adjusted rates of obesity (49.5%) compared with Mexican Americans (40.4%), all 
Hispanics (39.1%) and non-Hispanic whites (34.3%)6. 
The prevalence of obesity in US adults is significantly higher between 
minority women and Caucasian women. In 1988-1994, the prevalence of obesity 
in Non-Hispanic White women was 22.9%, 38.4% in Non-Hispanic Black women, 
and 35.4% of Mexican American women. In 2010, these prevalence rates were 
significantly higher at 32.2% of Non-Hispanic White women, 58.5% of Non-
Hispanic Black women, and 44.9% of Mexican American women7. 
 
1.2 Influenza Virus 
Influenza is one of the most widely spread human infectious diseases and 
causes significant morbidity and mortality every year. There are three types of 
influenza virus, type A, B, and C. Human influenza A infects mostly humans and 
several types of animals, including birds, pigs, and horses. Type B influenza is 
normally found only in humans, and type C is mostly found in humans, but has 
also been found in pigs and dogs.  Type A viruses typically cause influenza 
pandemics and are the most threatening in humans. Type A influenza viruses 
can be further classified based on two glycoproteins that exist on the surface of 
the virus called hemagglutinin (HA) and neuraminidase (NA). There are 17 
known different versions of HA and 9 known different versions of NA and these 
versions are assigned a specific number, helping to name a particular viral 
strain8.  
The influenza virus is typically rounded, but can also be elongated or 
irregularly shaped. The glycoproteins HA or NA rest on the surface. The HA 
protein aids in the attachment of the virus to the cell, so that it can enter into a 
host cell and start the infection process. HA proteins are also recognized by the 
human immune system through antibodies that will signal for an immune 
response10. The NA protein aids in helping the virus exit the host cell so that new 
viruses that were made inside the host cell can be released in order to infect 
more cells.  The influenza virus is enveloped, segmented, single-stranded RNA 
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virus. Inside the virus, there are eight segments of RNA that encode 11 proteins 
related to viral replication9. 
The potency of influenza virus lies in its ability to change, especially 
influenza virus A. This is why the flu vaccine must be changed from year to year. 
The influenza virus can change in two ways, through drift and shift. Antigenic 
drifting is a gradual, continuous change that results through mistakes that occur 
from gene replication, resulting in differences in the HA or NA proteins. Although 
the changes can be small, they may no longer be recognizable to the human 
immune system12. Antigenic shift, a much more unlikely occurrence, is an abrupt, 
major change in the virus that produces a new combination of the HA and NA 
proteins, which results in a pandemic. There have been 4 such flu pandemics, 
including the first flu pandemic of the 21st century- pandemic H1N19. 
 
1.3 Influenza Virus Infection and Immune Response 
Infection of the virus occurs from person to person when people infected 
with flu cough, sneeze, or talk and spread virus-laden droplets. The virus gains 
entry into the host through the respiratory tract and infects the host in their nose, 
throat, and lungs. Once the virus has gained entrance into the host, it can travel 
into the nucleus of the respiratory tract cells by binding their hemagglutinin 
glycoproteins to the sialic acid sugars on the epithelial cell surface, and then use 
their replication machinery in order to replicate and release viral particles to the 
surrounding cells, spreading the infection11. 
Upon infection by the virus, the innate immune system, or the non-specific 
immune system, responds first to the viral antigens.  Influenza A viral infection is 
sensed by infected cells via pattern-recognition receptors (PRRs) that recognize 
viral RNA, the main pathogen-associated marker pattern (PAMP) of influenza A 
viruses.  PRRs include toll like receptors (TLRs) and retinoic acid inducible gene-
1 (RIG-1).  Single stranded viral RNA bind to TLR7 and double-stranded viral 
RNA binds to TLR3 and RIG-1, signaling receptor cascades to produce 
proinflammatory cytokines and type I interferons including IFN-β and IFN-α that 
have strong antiviral activity exerted by inhibiting protein synthesis in host cells 
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and limiting viral replication.  These PRRs are located on cells of the innate 
immune system including macrophages and dendritic cells16. 
Antigen-presenting cells, specifically dendritic cells and macrophages, 
promote destruction of a virus by activating cytotoxic T-cells (CD8 T cells) or 
ingesting viruses through pinocytosis. In addition, they activate the adaptive 
immune response to create antibodies for the virus through class II MHC 
glycoproteins. The antigen-presenting cell processes antigen and presents it on 
class II MHC molecules that are recognized by CD4+ helper T cells in the lymph 
nodes. Virus-derived peptides in the host cell are also recognized by class I MHC 
glycoproteins. The peptides and the Class I MHC glycoprotein form a complex 
that activates the cloning and differentiation of CD8+ T cells to enhance viral 
clearance16. 
Helper T cells, once stimulated by the class II MHC antigen complex, 
make proteins that induce B cells to proliferate and cause its progeny to 
differentiate into antibody-secreting cells. Antigen-specific T-cell help is required 
for antibody responses14. When a B cell encounters the kind of antigen that 
triggers it to become active, it gives rise to many large cells known as plasma 
cells, which produce antibodies. Antigens from influenza viruses stimulate the B 
cells to release a variety of immunoglobulins, including IgG subclasses14,17. 
 
      
1.4 Influenza Vaccine 
Vaccinations are recommended to individuals in order to prevent viral 
infection and its spread. Vaccines help develop immunity to the influenza virus by 
imitating viral infection without causing illness15. The influenza vaccine varies by 
season, depending on the prediction of circulating strains. For the 2013-2014 
year, the seasonal trivalent vaccine was composed of two strains of type A 
viruses and one strain of type B. Because the flu vaccine is manufactured 
several months before flu activity begins, the strains that are used in the vaccine 
are predicted from the available evidence. If the prediction matches the 
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circulating strains, then good protection from flu infection occurs. If the prediction 
is less accurate, then the flu vaccine is less protective18. 
Upon vaccine inoculation, the immune system responds to the viral 
antigens in the vaccine, inducing both T and B memory cells that are poised to 
quickly respond to a future flu infection. Exposure to the viral antigen by a 
vaccine sustains memory of the antigen by long-lived antigen-specific B 
lymphocytes that were induced by the original exposure and that persist until a 
second encounter with the pathogen. The number of memory cells for a given 
antigen is highly regulated, remaining practically the same throughout the 
memory phase. When restimulated by the same antigen, the cells are able to 
respond quickly and remove the infection18. 
 
1.5 Immunoglobulin G Subclasses 
The glycoprotein immunoglobulin G (IgG) is a major effector molecule of 
the human humoral immune response and accounts for about 75% of the total 
immunoglobulins in plasma of healthy individuals. The other immunoglobulins, 
IgA, IgM, and IgD make up the remaining 25% of the total immunoglobulins29. 
    The four IgG immunoglobulin subclasses (IgG1, IgG2, IgG3 and IgG4) 
are more than 95% homologous in their amino acid sequences of the constant 
domains of the γ-heavy chains but show the most differences amongst each 
other in the amino acid composition and structure of the ‘hinge region.’ The 
length and flexibility of this hinge region varies among the IgG subclasses27. 
One of the most important attributes of IgG is its role in the complement 
activation initiation. Activation is started when C1 binds to sites on the Fc portion 
of human IgG27. IgG3 is the most potent activator of the complement system, 
followed by IgG1 and then IgG2. IgG4 is generally inactive in complement 
activation. Another important role of IgG is its role in clearance of antigens via 
phagocytosis28. 
Generally, antibody responses to protein antigens, including viral proteins, 
mainly involve IgG1 and IgG328.The precise roles of each IgG subclass are still 
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unclear, but certain antigens (bacterial and viral) can cause increases in selective 
subclasses of IgG28. 
1.6 Differences in the Immune Response by Racial Background 
          There is a large amount of information documenting the significant 
differences in the prevalence of obesity and chronic conditions within different 
ethnic groups, but the reasoning behind this is still largely unexplained. 
Differences in the levels of cytokines, immunoglobulins, and response after 
infection may contribute to these chronic conditions. Preliminary studies have 
been conducted to determine if genetics plays a role in these differences. One 
study by Ness, Haggerty, and Ferrell showed that African-American women were 
significantly more likely to carry allelic variants in cytokine genes known to 
upregulate proinflammatory cytokines. Many chronic conditions are tied to an 
inflamed state. The upregulation of the proinflammatory immune response may 
suggest that there is a race-specific genetic component that predisposes African 
American to chronic inflammatory conditions21. In addition, this upregulation of a 
proinflammatory state may also affect the immune response to vaccines. There is 
more information needed in order to see if there is a difference in immune 
response to influenza vaccination between the African-American and the White-
American populations. This study was done to determine if there is a difference 
in immune responses within the African-American and White-American 
populations. 
I hypothesized that the African-American population will have a stronger 
immune response to the vaccine compared to the White-American population 





Specific Aim and Hypothesis 
Specific Aim: To determine if the antibody response to the Influenza Vaccine 
differs in African Americans compared to that in Caucasians by looking at IgG1, 
IgG2, IgG3, and IgG4 subclasses of immunoglobulin G. 
Hypothesis: The antibody response to the Influenza Vaccine will be higher in 





3.1 Study Design: 
Subjects for this study were selected from participants of an ongoing, 
prospective, observational study taking place at the University of North Carolina 
Family Medicine Center. The original study gave participation eligibility to adult 
patients (> 18 years of age) that were scheduled to receive the 2013-2014 
trivalent, inactive seasonal vaccine. Participants were excluded upon the 
following criteria: under the age of 18, acute febrile illness, under 
immunosuppressive medicines in the last 4 weeks, pregnant or breastfeeding 
women, and diseases such as cancer (except skin cancer that is not melanoma), 
Human Immunodeficiency Virus, and Hepatitis C. 
At enrollment, informed consent, height, weight, and baseline blood 
samples were obtained from each participant. They were then administered one 
dose of the inactive 2013-2014 trivalent inactive vaccine one to one and a half 
inches into their deltoid muscle.  Participants returned to the center 25-28 days 
after the first administration to give a post-vaccination blood sample. PBMCs and 
serum were isolated from each blood sample collected pre and post vaccination. 
For this study, serum from women with BMIs between 30 and 35 kg/m2 with little, 
inconsistent, or no exercise were used. These participants were separated into 
one of two groups: African American or White American. 
 
3.2 Serum Collection: 
 Serum was collected before receiving the vaccine and again 25-28 days 
after receiving the vaccine. Blood was collected from patients at this time into a 
vacutainer tube and allowed to clot for 30-60 minutes at room temperature, then 
moved to a refrigerator. During time of collection, the tubes were centrifuged at 
800 x g for 10 minutes at 4°C using for IEC Centra MP4R. Serum was aliquoted 
into 500 microliters amounts using serum tubes and placed into an -80°C freezer. 
3.3 Influenza-specific ELISA for IgG  
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The enzyme-linked immunosorbent assay (ELISA) was used to identify 
the level of influenza-specific antibodies in serum. This method enabled analysis 
of antibody protein levels by immobilizing them in microplate wells using antigen-
antibody binding. The method employed by this study was the indirect ELISA 
method.  The vaccine antigen, diluted in coating buffer, was immobilized to the 
surface of the polystyrene microplate wells. The plate was then blocked with a 
block buffer of milk in order to cover all unsaturated surface-binding sites of the 
microplate wells. Next, the subject serum was added. Following an incubation 
and a washing, a secondary, mouse anti-human IgG (IgG1-IgG4) antibody 
conjugated with horse radish peroxidase (HRP) was added to bind to the specific 
primary antibody from the participant’s serum. Following a wash, the enzyme 
substrate was added to catalyze a reaction that induces a color change in the 
substrate due to HRP activity. This color change signal was measured with an 
ELISA plate reader by measuring the absorbance at 450 nm. Increased enzyme 
activity (detected by a darker color reaction) was directly correlated with antibody 
concentration. 
The ELISA procedure spanned over two days. Prior to the start of the 
experiment, an optimization assay was run for each ELISA component at 
different concentrations to determine the optimal dilutions for vaccine antigen, 
serum, and secondary antibody with HRP. For this project, each subclass of IgG 
(IgG1, IgG2, IgG3 and IgG4) was measured, and therefore each one was 
optimized individually. The optimal vaccine antigen dilution for each antibody was 
chosen to be 1:160. 
Following optimization, the serum from the participants and the secondary 
antibody with HRP was diluted according to the following table: 
Antibody Plate Secondary antibody 
with HRP 
Serum Dilution. 
IgG1 1:1000 1:6400 
IgG2 1:1000 1:100 
IgG3 1:1000 1:400 
IgG4 1:500 1:200 
13 
 
Table 1. Dilutions of secondary antibodies and serum dilutions used during 
ELISA runs for IgG1, IgG2, IgG3, and IgG4. 
 
3.4 Specific Details for Analysis of Antibody Levels in Serum using ELISA: 
Materials: 
Clear 96 well plates 
Plate covers 
Multi-channel precision pipettors with disposable plastic tips 
Plate Reader 
Reagents 
Coating Buffer 0.2 M sodium carbonate/bicarbonate solution in PBS 
wash 
Wash buffer 330 mL phosphate buffer solution, 3000 mL of distilled 
H2O, and 1.6 mL of Tween-20 
Block Buffer 2.4 grams of nonfat dry milk in 80 mL of Coating Buffer  
Dilution Buffer  
Detection/Secondary 
Antibody 
Mouse anti-human antibody for IgG1, IgG2, IgG3, and 
IgG4 with HRP conjugate 
Vaccine Antigen Diluted in Coating Buffer – 1:160 dilution 
Horseradish Peroxidase Attached to detection antibody; acts as enzyme 
conjugate 
Enzyme Substrate TMB Substrate in Peroxide solution 
Stop Solution 2M sulfuric Acid 
Primary Antibody Antibodies in the serum of study participants 
Table 2. Reagents used during ELISA. 
On the first day, vaccine was diluted to a 1:160 using Coating buffer 
solution. The plates were coated with the diluted vaccine, adding 50 microliters of 
the vaccine solution into each well of a 96 well plate. The plates were stored in a 
moist plastic bag in a 4°C refrigerator overnight.   
On the second day, the solution in the wells was discarded and each well 
was coated with 200 microliters of Block buffer. The wells were then incubated in 
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a 37°C incubator for 1 hour. The plates were then removed and washed with 1x 
Phosphate Buffer Saline Solution with Tween-20 twice. The serum from the 
participants was diluted according to Table 1. The serum was added to the wells 
in triplicates of 50 microliters each, filling three wells with the same diluted serum. 
Three wells were filled with a control serum and three wells were filled with 
dilution buffer without serum to provide a background measurement. The plates 
were then incubated for two hours at 37°C and washed with 1x Phosphate Buffer 
Saline Solution with Tween-20. 
After this wash, the secondary antibody with HRP was added. Each plate 
received a different antibody: IgG1, IgG2, IgG3, or IgG4. These antibodies were 
diluted according to Table 1.  Each well received 50 microliters of antibody 
solution in Dilution buffer. The plates were then incubated at 37°C for one hour 
and washed with 1x Phosphate Buffer Saline Solution with Tween-20.   
After washing, 100 microliters of TMB substrate solution was added to 
each well, catalyzing the reaction of the horseradish peroxidase conjugate to 
change the substrate’s color. This reaction was allowed to continue for thirty 
minutes exactly under aluminum foil. The reaction was stopped using 100 
microliters of 2 M sulfuric acid in each well. The optical density was measured for 
each well at 450 nm wavelength. 
3.5 Data Analysis: 
After each plate read, the blank measurements were compared to the 
readings from the positive control wells. If the absorbance measurements from 
the control wells were significantly higher than those of the blank wells, the plate 
measurements were kept. If not, the ELISA protocol was rerun for that plate. 
The blank measurements on each plate were subtracted from each well 
containing a sample. Then, the average, standard deviation, and the coefficient 
of variation were calculated for each triplicate.  The coefficient of variation was 
kept if it was 15% or less. If the coefficient of variation was higher than 15%, the 
triplicates were observed for an outlier, which was deleted. If the coefficient 
remained high, then the sample was rerun. 
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The average of the blank measurements from all plates for a certain 
antibody was added to the average reads for each sample. Then, the percent 
change was calculated using the formula: 
PERCENT INCREASE = �
(POST VACCINATION VALUE)
(PRE VACCINATION VALUE)
𝑋100� − 100 
The data was analyzed using the program GraphPad Prism 6.0.  A 






4.1 Demographics of the Study Population 
Participants were classified into two groups: African American and 
Caucasian.  All were obese, which was defined as a BMI greater than 30 and 
less than a BMI of 35.  Past studies have been done that have demonstrated a 
decreased antibody response in obese individuals compared to healthy weight 
individuals, so women at similar BMIs were chosen to eliminate potential 
confounding variables. Furthermore, using a survey developed at the Gillings 
School of Global Public Health at the University of North Carolina Chapel Hill, 
levels of physical activity per week was assessed. The immune system can be 
influenced acutely by exercise, both positively by moderate exercise and 
negatively by heavy exertion19. Thus, this study only included participants with 









































1507 34.13 70 None  1523 31.47 35 None 
1514 30.22 70 None  1537 32.92 73 None 
1515 32.84 41 None  1540 34.76 45 None  
1519 31.75 54 None  1635 32.60 56 None 
1522 33.47 58 None  1649 33.10 66 Type 2 
1528 31.07 58 None  1699 33.65 56 Type 2 
1529  31.00 65 Type 2  1709 31.24 49 None 
1570 30.00 71 None  1766 34.38 56 Type 2 
1587 34.54 66 Type 2  1794 32.34 63 None 




30.61 48 None 
1626 31.00 37 None  1898 31.00 57 Type 2 
1631  33.57 54 None  1908 33.67 57 None 




33.98 29 Type 2 
1651 30.69 47 None  1925 31.35 43 Type 2 
1680 31.17 62 None  1961 30.64 50 None 
1788 33.30 51 None  1972 31.75 61 Type 2 
1797 31.31 52 None  2078 31.77 57 None 
1804 32.95 41 None      
1853 33.83 48 Type 2      
1899 32.55 40 None      
1927 34.62 62 None      
1952  31.45 43 None      
Table 3. Demographics of all participants in this study. All were women with little, 
no, or inconsistent exercise with BMIs between 30 and 35 kg/m^2. The average 
age of Caucasian women participating in the study was 55 years with a standard 
deviation of 10 years. The average age of African American women was 53 
years with a standard deviation of 11 years. The average BMI of Caucasian 
participants was 32.4 + 1.5 kg/m2 and the average BMI of African Americans was 
32.4 + 1.3 kg/m2.  
4.2 Antibody Levels in Serum – Percent Change from Pre Vaccination to 
Post Vaccination 
The null hypothesis for each IgG subclass was that there was no 
difference in the percent increase of antibody levels pre and post vaccination 
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between the two groups, Caucasians and African Americans. A Wilcoxon rank-
sum test was used to analyze the significance of each subclass because the 
assumption of a normalized population could not be assessed. 
For Caucasians, the IgG1 antibody level in serum increased at an average 
of 191.3% from pre vaccination to post vaccination with a standard error of + 
46.2%. The sample size of this group was 22 people.  For African-Americans, the 
IgG1 antibody level in serum increased at an average of 143.6% from pre 
vaccination to post vaccination with a standard error of + 41.7%.  The sample 
size of this group was 17 people.  The difference between the means of these 
two groups for IgG1 was 24.41% ± 83.66%. For IgG1, the p-value was 0.4876, 
greater than the significance level of 0.05. Thus, the two groups did not have 
significantly different levels of increase in IgG1. The two groups are compared 
below in Graph 1. 
 
Graph 1. The IgG1 antibody levels for Caucasian and African American 
participants increased from pre vaccination to post vaccination at 191.3% + 
46.2% and 143.6% + 41.7% respectively.  
The IgG2 antibody was in negligible levels in the population.  For this 
year’s vaccine antigen, IgG2 was not highly expressed and was unable to be 
detected using the indirect ELISA. 
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For Caucasians, the IgG3 antibody level in serum increased at an average 
of 129.5% from pre vaccination to post vaccination with a standard error of + 
31.1%. The sample size of this group was 21 people.  For African-Americans, the 
IgG3 antibody level in serum increased at an average of 153.9% from pre 
vaccination to post vaccination with a standard error of + 87.1%.  The sample 
size of this group was 16 people.  The difference between these two means was 
24.4% with a standard error of 83.7%. For IgG3, the p-value was 0.3818, greater 
than the significance level of 0.05. Thus, the two groups did not have significantly 
different levels of increase in IgG3. The two groups are compared below in 
Graph 2. 
 
Graph 2. The IgG3 antibody levels for Caucasian and African American 
participants increased from pre vaccination to post vaccination at 129.5% + 
31.1% and 153.9%  + 87.1% respectively.  
For Caucasians, the IgG4 antibody level in serum increased at an average 
of 75.9% from pre vaccination to post vaccination with a standard error of + 
40.9%. The sample size of this group was 22 people.  For African-Americans, the 
IgG4 antibody level in serum increased at an average of -2.1% from pre 
vaccination to post vaccination with a standard error of + 9.5%.  The sample size 
of this group was 17 people.  The difference between these two means was -
78.1% with a standard error of 47.4%. For IgG4, the p-value was 0.0264, less 
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than the significance level of 0.05. Thus, the two groups did have significantly 
different levels of increase in IgG4. The two groups are compared below in 
Graph 3. 
 
Graph 3. The IgG4 antibody levels for Caucasian and African American 
participants increased from pre vaccination to post vaccination at 75.9% + 40.9% 
and -2.1% + 9.5% respectively.  
The data was also stratified to quantify how much each group’s antibody 
levels increased.  The graphs below compare stratified percentage increases in 
the immunoglobulin levels pre and post vaccination within Caucasians compared 
to that in African Americans. 
 
Graph 4. The percent increases in IgG1 from pre to post vaccination were 




Graph 5. The percent increases in IgG3 from pre to post vaccination were 
stratified by groups of percentage increases.  
 
Graph 6. The percent increases in IgG4 from pre to post vaccination were 














      In this study, the immune responses of African American and Caucasian 
women were compared by looking at the levels of antibody in serum pre-
vaccination and post-vaccination. We had hypothesized that the African 
American population would have a stronger immune response due to previous 
studies that have shown higher levels of gene expression of proinflammatory 
cytokines in the African American population21. As with viral infection, variability 
in the immune response to vaccination is likely to be influenced by genotype22.  
These proinflammatory cytokines include interleukin-1 alpha and interleukin-6.   
     Cytokines play a major role in the innate immune system. Interleukin-1 is a 
cytokine produced by activated macrophages23. IL-1 plays a necessary role in 
the generation of a differentiation signal directly related to the B-cell, without 
which the subsequent B-cell maturation to Ig-secreting cells does not occur24.  
Interleukin-2 promotes the clonal selection of B-cells in humoral immunity.  
Interleukin-6, interleukin-4, interleukin-5, interleukin-10, and TGF-β all promote 
the differentiation of B-cells to plasma cells that release antibodies23.  
The increased gene expression of these cytokines prompted a hypothesis 
of higher levels of antibody release with the African American population when 
compared to that of Caucasians. However, the study depicted no difference in 
the increase of IgG1 and IgG3 pre- and post- vaccination with the flu vaccine. In 
IgG4, there was a significantly higher average percentage increase in 
Caucasians compared to African Americans, which is opposite of what was 
expected. For IgG2, the ELISA method used to detect the antibodies was not 
able to detect the antibody at the titer levels currently in the population.  Other 




 Comparing the stratified percent increases shown in Graph 4, Caucasians 
had a greater percentage of participants that had a percentage increase in IgG1 
of over 140% from pre to post vaccination as compared to African Americans.  
This trend can also be seen in graph 5, where the percentage of Caucasian 
participants that had a percent increase of IgG3 greater than 140% is higher than 
the percentage of African American participants that had a percent increase of 
IgG3 greater than 140%.  
The significantly higher average percent increase in IgG4 within the 
Caucasian women compared to African American women from pre to post 
vaccination was supported by data displayed in Graph 6.  The stratified 
percentage increases show that Caucasians had a less percentage of 
participants that had antibody increases at 0% or less compared to African 
Americans. 
An explanation for the decreased immune response in African Americans 
is the high levels of chronic conditions such as diabetes and hypertension that 
exist within this group. The presence of secondary characteristics associated 
with these chronic conditions could decrease the effectiveness of their immune 
response and contribute to the lower average percentage increase in IgG4 
antibody compared to Caucasians seen in this study. Furthermore, this could 
explain the lesser percentage of African Americans who experienced greater 
than a 140% increase pre to post vaccination in IgG3 and IgG1 as compared to 
Caucasians. Studies have shown a lower antibody response comparing pre and 
post vaccination in diabetic patients compared to non-diabetic patients25. 
This could have interesting implications in public health. A past study has 
shown that IgG4 can block cytotoxicity mediated by antibody-activated effector 
cells in Malaria13. Thus, it is unclear now if lower levels of IgG4 can be 
associated with a weakened immune response to the influenza virus and may 
serve as a potential benefit for the African American population. Low IgG4 levels 
in the African American population may also be due to a natural, ancestral low 
levels of IgG4 that were inherent in this population for greater immunity to 
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Malaria. Furthermore, the stronger increases in the Caucasian population, 
indicated by the greater percentage of these participants who had percentage 
increases pre and post vaccination of IgG1 and IgG3 that were greater than 
140%, could indicate that the Caucasian population may be in a chronic inflamed 
state. Thus, it may not be beneficial to the Caucasian population to have more 
participants have large increases in antibody response. 
 
5.2 Limitations and Recommendation for Further Studies 
This study had several limitations. The first was its small sample size. The 
study had 22 participants in the Caucasian group and 17 participants in the 
African American group. However, in the IgG3 group, only data from 21 
Caucasians and 16 African Americans were used due to inconsistent ELISA 
readings. The low sample size decreases the power of this study and decreases 
its ability to draw significant conclusions. Further studies could be done that 
pulled a larger sample size by recruiting participants specifically for this study, 
instead of pulling from an already created subset.  
Another limitation to this study was that height was self-reported. This 
could have skewed BMI readings because of inconsistent height reports. To 
avoid this in future studies, height should be recorded by data collectors. The 
marker of obesity used was BMI, which does not directly measure body fat and 
could be a limitation of the study. Furthermore, racial status was self-reported 
and did not distinguish between those who were racially mixed, despite the 
known 7-20% White admixture within African Americans, which would tend to 
reduce observed associations21. 
Further studies could be done by stratifying each population by chronic 
conditions to compare the immune response between races with similar chronic 
conditions. In this way, the confounder of chronic disease can be removed.  
Another potential addition that could be added to this study would be to follow 
participants to see if they develop flu-like symptoms and compare this to their 
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IgG levels. This could provide insight into which patients have lower antibody 
responses as well as weakened immune systems. Another recommendation for 
future studies would be to look at CD8+ and CD4+ T-cell responses and cytokine 
levels to have a closer understanding of any differences in the immune response 
that may exist between the two races. 
 The age range of African Americans was 37 years to 71 years with an 
average age of 55 years. The age range of Caucasians was between 29 years to 
73 years with an average age of 53 years. At an older age, the immune response 
to the flu vaccine is diminished and a similar age group should be used for that 
reason26. In future studies, a set age range should be made in order to account 
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